NO903851L - Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter. - Google Patents

Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.

Info

Publication number
NO903851L
NO903851L NO90903851A NO903851A NO903851L NO 903851 L NO903851 L NO 903851L NO 90903851 A NO90903851 A NO 90903851A NO 903851 A NO903851 A NO 903851A NO 903851 L NO903851 L NO 903851L
Authority
NO
Norway
Prior art keywords
loweralkyl
hydrogen
aryl
pyrimidaminamines
medicines
Prior art date
Application number
NO90903851A
Other languages
English (en)
Other versions
NO903851D0 (no
Inventor
Richard Charles Effland
Joseph Thomas Klein
Larry Davis
Gordon Edward Olsen
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of NO903851D0 publication Critical patent/NO903851D0/no
Publication of NO903851L publication Critical patent/NO903851L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Oppfinnelsen vedrører N-heteroaryl-4-pyrimldlnaminer med formelen. der Rer hydrogen, laverealkyl, aryl eller aryllavere-alkyl; Rog Rer uavhengig av hverandre hydrogen eller laverealkyl, eller Rog Rtatt sammen er aryl; Rog Rg er uavhengig av hverandre hydrogen eller laverealkyl, eller Rog Rtatt sammen er aryl; X er hydrogen, halogen, cyano, nltro, amlno, laverealkyl, laverealkoksy, tri fluormetyl eller. der Y er hydrogen, halogen eller laverealkyl; m er et helt tall fra 1 til 3; og farmasøytisk aksepterbare syretl1setningssalter derav og der de kan anvendes geometriske og optiske lsomerer og racemlske blandinger derav. Forbindelsene 1 oppfinnelsen kan utnyttes som hukommelsesforbedrende midler og som analgetiske midler.
NO90903851A 1989-09-05 1990-09-04 Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter. NO903851L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/402,415 US4983608A (en) 1989-09-05 1989-09-05 N-substituted-4-pyrimidinamines and pyrimidinediamines

Publications (2)

Publication Number Publication Date
NO903851D0 NO903851D0 (no) 1990-09-04
NO903851L true NO903851L (no) 1991-03-06

Family

ID=23591798

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90903851A NO903851L (no) 1989-09-05 1990-09-04 Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.

Country Status (18)

Country Link
US (1) US4983608A (no)
EP (1) EP0417584B1 (no)
JP (1) JPH07116181B2 (no)
KR (1) KR0162641B1 (no)
AT (1) ATE163012T1 (no)
AU (1) AU626450B2 (no)
CA (1) CA2024572C (no)
DE (1) DE69032020T2 (no)
DK (1) DK0417584T3 (no)
ES (1) ES2112830T3 (no)
FI (1) FI904327A0 (no)
GR (1) GR3026318T3 (no)
IE (1) IE903213A1 (no)
IL (1) IL95568A (no)
NO (1) NO903851L (no)
NZ (1) NZ235145A (no)
PT (1) PT95202B (no)
ZA (1) ZA907033B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
ES2274634T3 (es) * 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ES2306671T3 (es) * 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
CN1429222A (zh) * 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) * 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
SI1534286T1 (sl) 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
MXPA05001096A (es) * 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
KR20120062863A (ko) * 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
MXPA06013165A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
EP1751142A1 (en) * 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidines derivatives for the treatment of abnormal cell growth
JP2007537235A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20060058525A1 (en) * 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
CA2584295C (en) * 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
MX2007007272A (es) * 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
WO2007027238A2 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
EP2301928A1 (en) * 2005-07-30 2011-03-30 AstraZeneca AB Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
WO2007036732A1 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
CN101657422A (zh) 2007-04-13 2010-02-24 塞诺菲-安万特股份有限公司 过渡金属催化的n-氨基吲哚的合成
GB2578973B (en) * 2015-04-17 2020-08-26 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752610A (en) * 1985-12-04 1988-06-21 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing properties
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4806554A (en) * 1988-01-11 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. Pyrazol and indazolpyridinamines
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines

Also Published As

Publication number Publication date
DK0417584T3 (da) 1998-09-23
NO903851D0 (no) 1990-09-04
KR910006277A (ko) 1991-04-29
FI904327A0 (fi) 1990-09-03
IL95568A0 (en) 1991-06-30
ZA907033B (en) 1991-06-26
GR3026318T3 (en) 1998-06-30
ES2112830T3 (es) 1998-04-16
PT95202B (pt) 1997-06-30
CA2024572A1 (en) 1991-03-06
IL95568A (en) 1995-01-24
EP0417584A2 (en) 1991-03-20
CA2024572C (en) 2000-09-26
DE69032020D1 (de) 1998-03-12
NZ235145A (en) 1992-12-23
DE69032020T2 (de) 1998-07-09
EP0417584B1 (en) 1998-02-04
AU6208990A (en) 1991-03-14
IE903213A1 (en) 1991-03-13
EP0417584A3 (en) 1992-02-26
US4983608A (en) 1991-01-08
KR0162641B1 (ko) 1998-12-01
AU626450B2 (en) 1992-07-30
ATE163012T1 (de) 1998-02-15
JPH0393784A (ja) 1991-04-18
JPH07116181B2 (ja) 1995-12-13
PT95202A (pt) 1991-05-22

Similar Documents

Publication Publication Date Title
NO903851D0 (no) Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
DK441187D0 (da) Alfa-alkyl-4-amino-3-quinolinmethanoler og 1-(4-aralkylamino-3-quinolinyl)alkanoner, deres fremstilling og anvendelse
DK0637586T3 (da) 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
DK0402752T3 (da) N-Heteroaryl-purin-6-aminer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
HUT57773A (en) Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds
NO903388D0 (no) Fremgangsmaate for fremstilling av 1-(pyridinylamino)-2-pyrrolidinoner, samt anvendelse som medikamenter.
NO903390D0 (no) Fremgangsmaate for fremstilling av 2,3-dihydro-1-(pyridinylamino)-indoler og deres anvendelse som legemidler.
ES2044043T3 (es) Procedimiento para preparar n-piridinil-9h-carbazol-9-aminas.
NO894445D0 (no) Fremgangsmaate for fremstilling av 1,2,3,4-tetrahydro-1,9-acridindiaminer, og deres anvendelse som medikamenter.
BR0212932A (pt) Derivados de alquilaminopiridazinona substituìdos, processo para a preparação destes, composição farmacêutica contendo os mesmos e seus usos
NO913543L (no) Fremgangsmaate for fremstilling av 3-(1h-indazol-3-yl)-4-pyridinaminer og mellomprodukter, og anvendelse som medikamenter.
DK592589D0 (da) Kondenserede heterocycliske derivater af 1,2,3,4-tetrahydroacridin, deres fremstilling og anvendelse
DK0401779T3 (da) 4,5,5a,6-Tetrahydro-3H-isoazolo(5,4,3-kl)acridinderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler